Dr. Reddy’s to Acquire a Portfolio of 42 Abbreviated New Drug Applications (ANDA) in the US

Shots:

• Dr. Reddy’s acquires a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the US, including >30 generics injectable
• The focus of the acquisition is to enhance Dr. Reddy’s injectable portfolio in the US and globally
• Dr. Reddy’s will launch the products within the next one to two years and according to IQVIA the products produced ~$645M revenue in 2018 in the US 

Click here to read full press release/ article | Ref: Dr. Reddy’s | Image: Twitter